Research Activities

Research Activities

Home › Research Activities › CiRA IP

CiRA IP

Intellectual Property of CiRA

As of November 2015, Kyoto University holds basic patents related to iPS cell technology in the following countries and regions.


Australia, Austria, Belgium, Bulgaria, Canada, China, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, Kazakstan, Liechtenstein, Mexico, the Netherlands, New Zealand, Portugal, Russia, Singapore, Spain, South Africa, South Korea, Sweden, Switzerland, Turkey, the United Kingdom and the United States.


In Japan

Patents describing induced pluripotent stem cell (iPSC) technologies filed by Kyoto University have been granted by the Japan Patent Office. The outlines of the claimed inventions are as follows:


JP4183742

A method for preparing iPSC through the introduction of four reprogramming genes (Oct3/4, Sox2, Klf4, c-Myc) into somatic cell.

JP4411362

A method for preparing iPSC through the introduction of three reprogramming genes (Oct3/4, Sox2, Klf4) into somatic cell and the culturing in the presence of bFGF.

JP4411363

A method for preparing somatic cells, which comprise production process for the generation of iPSC generated either through the introduction of three reprogramming genes (Oct3/4, Sox2, Klf4) into somatic cell and the culturing in the presence of bFGF, or through the introduction of four reprogramming genes (Oct3/4, Sox2, Klf4, c-Myc) into somatic cell, and the generation of somatic cell from such iPSC through induced differentiation.

JP5098028
  • (A) A method for preparing iPSC through the introduction of specific gene families (an Oct3/4 family , a Klf4 family, a Myc family and a Sox2 family genes) *1 into somatic cell.
    (wherein at least one of specific gene family for the introduction into the somatic cell is omissible on the condition that corresponding gene is endogenously expressing gene in the somatic cell.)

  • (B) A method for preparing iPSC through the introduction of specific gene families (an Oct3/4 family , a Klf4 family and a Sox2 family genes) *1 into somatic cell and culture in the presence of bFGF.
    (wherein at least one of specific gene family for the introduction into the somatic cell is omissible on the condition that corresponding gene is endogenously expressing gene in the somatic cell.)

  • (C) A method for preparing a differentiated cell through the induced differentiation of iPSC prepared under the above identified process (A) or (B).

JP5248371
  • (A) Inducing agent to induce iPS cells in the condition of culturing in the presence of bFGF, comprising the three genes Oct3/4, Klf4, and Sox2 or gene products thereof.

  • (B) Inducing agent to induce iPS cells, comprising the four genes Oct3/4, Klf4. Sox2, and c-Myc, or gene products thereof.

JP5467223

A method for producing induced pluripotent stem cells, comprising the following (1) to (3) steps;

  • (1) selecting combination of genes whose insertion into somatic cells induce expression of the endogenous Oct3/4 gene and the Nanog gene from among genes displaying specific or high-level expression in ES cells, genes encoding factors activated by Wnt signaling or LIF signaling, genes essential to the maintenance of pluripotency in ES cells, and the family genes thereof,

  • (2) introducing the combination of genes selected in step (1) into somatic cells, and

  • (3) culturing the cells obtained in step (2).

(*1) The term "specific gene families" stands for the set of gene families each of which is specifically identified as :

  • - Oct family corresponds to Oct3/4
  • - Klf family consists of Klf2 and Klf4
  • - Myc family consists of c-Myc, N-Myc, L-Myc and T58A (mutational gene of c-Myc)
  • - Sox family consists of Sox1, Sox2, Sox3, Sox15 and Sox17

Overseas

As of January 2016, patent applications had been filed in countries and regions for iPS cell-related fundamental patents claimed by Kyoto University.

Australia, Austria, Belgium, Bulgaria, Canada, China, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Kazakstan, Liechtenstein, Mexico, the Netherlands, New Zealand, Portugal, Russia, Singapore, Spain, South Africa, South Korea, Sweden, Switzerland, Turkey, the United Kingdom and the United States.

The scope of the patents obtained in Europe and the United States is as set out below.


US8,048,999

A reprogramming factor comprising genes of an Oct family, a Klf family, and a Myc family.
A reprogramming factor comprising genes of an Oct family and a Klf family, and a cytokine.

US8,058,065

A method for preparing iPSC through the introduction by retroviral vector(s) comprising four reprogramming genes (Oct3/4, Sox2, Klf4, c-Myc) into somatic cell and the post culturing on a fibroblast feeder layer or an extracellular matrix with ES cell growth condition.

US8,129,187

A method for preparing mammalian somatic cell(s) by differentiating iPSC obtained through the use of four reprogramming genes (Oct3/4, Sox2, Klf4, c-Myc) under substantially the same process of above US8,058,065 patent.
A method for preparing mammalian somatic cell(s) by differentiating iPSC obtained through the use of three reprogramming genes (Oct3/4, Sox2, Klf4) under substantially the same process of above US8,058,065 patent.

US8,278,104

A method for preparing iPSC by nuclear reprogramming of a mammmalian somatic cell, comprising the steps of introducing into the mammalian somatic cell one or more retroviral vectors comprising reprogramming geness (Oct3/4, Klf4, Sox2) , and culturing the transduced somatic cell in the presence of a cytokine.

EP1970446

A reprogramming factor comprising genes or gene products of an Oct family, a Klf family, and a Myc family.
A reprogramming factor comprising genes or gene products of an Oct family and a Klf family, and a cytokine.

  • * Oct family includes several similar genes such as Oct3/4, Oct1A, Oct6.
  • * Klf family includes several similar genes such as Klf4, Klf1, Klf5.
  • * Myc family includes several similar genes such as c-Myc, L-Myc, N-Myc.
  • * Cytokine includes proteins such as bFGF,SCF and LIF.
  • * Factors such as Sox2 unmentioned in the claim are also included in the patent right even though they are used in reprogramming or not.
go top